{
    "clinical_study": {
        "@rank": "117786", 
        "arm_group": {
            "arm_group_label": "BPX-501 T cells and AP1903", 
            "arm_group_type": "Experimental", 
            "description": "TCR alpha beta depleted graft infusion with addback of BPX-501 T cells.\nAP1903: Dimerizer drug administered to subjects who develop Grade III-IV acute GVHD, Grade II gut/liver acute GVDH or Grade I/II skin-only acute GvHD which is non-responsive after 7 days of standard of care treatment"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate pediatric patients with malignant or non-malignant blood cell\n      disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa\n      and beta cells that comes from a partially matched family donor.  The study will assess\n      whether immune cells, called T cells, from the family donor, that are specially grown in the\n      laboratory and given back to the patient along with the stem cell transplant can help the\n      immune system recover faster after transplant. As a safety measure these T cells have been\n      programmed with a self-destruct switch so that they can be destroyed if they start to react\n      against tissues (Graft versus host disease)."
        }, 
        "brief_title": "Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Acute Lymphoblastic Leukemia", 
            "Leukemia Acute Myeloid", 
            "Lymphoma, Non-Hodgkin", 
            "Myelodysplastic Syndrome", 
            "Immunologic Deficiency Syndromes"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hematologic Diseases", 
                "Immunologic Deficiency Syndromes", 
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
                "Leukemia, Myeloid, Acute", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase 1/2 study evaluating the safety and feasibility of BPX-501 T cells infused\n      after partially mismatched, related, TCR alpha beta T cell depleted hematopoietic stem cell\n      transplant (HSCT) in pediatric patients. The purpose of this clinical trial is to determine\n      whether BPX-501 infusion can enhance immune reconstitution and retain the graft versus\n      leukemia (GVL) effect, with the potential for reducing the severity and duration of severe\n      acute GvHD.  The trial will evaluate the treatment of GvHD by the infusion of dimerizer drug\n      (AP1903) in those subjects who present with Grade III-IV acute GVHD, as well as those\n      subjects with Grade II gut/liver GvHD or with Grade I/II GvHD (skin only) who progress or do\n      not respond within 7 days to standard of care treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children with life-threatening hematological malignancies, deemed eligible for\n             allogeneic stem cell transplantation\n\n          -  Children with non-malignant disorders amenable to be cured by an allograft\n\n          -  Lack of HLA identical donor\n\n          -  Life expectancy > 10 weeks\n\n          -  Lansky/Karnofsky score  > 50, WHO > 4\n\n        Exclusion Criteria:\n\n          -  Grade >II acute GvHD or chronic extensive GvHD at the time of inclusion\n\n          -  Patient receiving an immunosuppressive treatment for GvHD treatment at the time of\n             inclusion\n\n          -  Dysfunction of liver (ALT/AST > 5 times normal value, or bilirubin > 3 times normal\n             value), or of renal function (creatinine clearance < 30 ml / min)\n\n          -  Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive\n             heart failure or left ventricular ejection fraction <40%)\n\n          -  Current active infectious disease (including positive HIV serology or viral RNA)\n\n          -  Serious concurrent uncontrolled medical disorder\n\n          -  Pregnant or breast feeding female patient\n\n          -  Lack of parents' informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "21 Years", 
            "minimum_age": "3 Months"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065869", 
            "org_study_id": "BP-004"
        }, 
        "intervention": {
            "arm_group_label": "BPX-501 T cells and AP1903", 
            "intervention_name": "BPX-501 T cells and AP1903", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ALL", 
            "AML", 
            "hematologic neoplasms", 
            "hematologic malignancies", 
            "primary immune deficiences"
        ], 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "contact": {
                "email": "aurelie.banquet@opbg.net", 
                "last_name": "Aurelie Bauquet"
            }, 
            "facility": {
                "address": {
                    "city": "Rome", 
                    "country": "Italy", 
                    "zip": "00161"
                }, 
                "name": "IRCCS Ospedale Pediatrico Bambino Ges\u00f9"
            }, 
            "investigator": {
                "last_name": "Franco Locatelli", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Study of CaspaCIDe T Cells From an HLA-partially Matched Family Donor After Negative Selection of TCR Alpha Beta T Cells in Pediatric Patients Affected by Hematological Disorders", 
        "other_outcome": {
            "measure": "Incidence of non-relapse mortality", 
            "safety_issue": "No", 
            "time_frame": "180 days and 1 year"
        }, 
        "overall_official": {
            "affiliation": "Bambino Ges\u00f9 Children's Hospital", 
            "last_name": "Franco Locatelli", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: The Italian Medicines Agency"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the maximum tolerated and/or recommended dose of BPX-501 cells.", 
            "measure": "Number of participants with serious and non-serious adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065869"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Time to reach alpha/beta positive CD3+ cell count > 500/ul; CD4+ cell count > 200/ul; CD8+ cell count > 200/ul", 
            "measure": "Time to immune reconstitution", 
            "safety_issue": "No", 
            "time_frame": "Up to 12 months"
        }, 
        "source": "Bellicum Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bellicum Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}